Latest News

CMS proposes deeper 340B drug payment cuts for hospitals, reshaping outpatient cancer economics, consolidation incentives, and patient cost-sharing.

The results jeopardize the accelerated approval of adagrasib plus cetuximab for KRAS G12C–mutated mCRC.

FDA issues Complete Response Letter for manganese chloride tetrahydrate (Orviglance), an oral liver MRI contrast agent for renal-impaired patients.

During a live event, Andrew Brunner, MD, and participants discussed second-line therapy selection in lower-risk MDS following ESA failure.

Building on these data, the ongoing phase 3 BATTMAN trial is exploring botensilimab plus balstilimab in refractory MSS mCRC.

A Type B meeting enabled progress toward initiation of US dosing in a phase 3 trial of a radioligand antibody-drug conjugate for metastatic castration-resistant prostate cancer.

Mature 13-year data show radiotherapy and temozolomide yield similar survival in low-grade glioma, but molecular subtype, not treatment order, predicts outcomes.

The next-generation KRAS G12C inhibitor improved survival vs the approved first-generation agents sotorasib and adagrasib.

Virtual behavioral health embedded in community oncology boosts access for Medicaid and Black patients, easing distress and improving quality of life.

During a live event, Sikander Ailawadhi, MD, and participants discussed treatment selection for a patient with heavily pretreated multiple myeloma who was not a candidate for CAR T-cell therapy and had exhausted both BCMA and GPRC5D-targeted bispecific options.

The zoldonrasib data build on the recent historical breakthrough with daraxonrasib in PDAC.

ASCO 2026 data reshapes lung cancer care, highlighting durable ALK control, new EGFR options, bispecific first-line gains, and SCLC progress.

Data link food deserts to metastatic breast cancer mutations and shorter survival, urging oncologists to screen for food insecurity.

Experts weigh leading IO/TKI combos for advanced RCC, comparing trials, toxicities, metastasis sites, and CNS strategy to personalize first-line care.

A randomized comparison of ATG, PTCy, and a combination helped characterize the similarities and differences of these regimens used as GVHD prophylaxis in stem cell transplant.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

ASCO 2026 highlights, FDA moves, and AI mammography sharpen breast cancer care—ADCs, ctDNA, and de-escalation reshape treatment and screening debates.

FDA oncology Q2 2026 brings major breast, prostate and kidney cancer approvals, split ODAC votes, and RP1 melanoma setback heading into Q3.

During a live event, Syed Abbas Ali, MBBS, and participants discussed treatment selection for a patient who has not yet received BCMA-targeted therapy after a second relapse of multiple myeloma.

Phase 3 MANGROVE shows chemo-free zanubrutinib plus rituximab extends PFS in untreated mantle cell lymphoma, with no new safety issues.

The clinicopathologic gene expression profile was granted the BDD status by the FDA for patients with T1b and T2a melanoma.

June 2026 FDA oncology updates bring major breast cancer shifts plus new prostate and kidney approvals, while melanoma and NET imaging decisions loom.

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).

During a live event, Zev Wainberg, MD, and participants discussed frontline immunotherapy selection in advanced HER2-negative gastrointestinal cancers.

Catherine Coombs, MD and oncologists weigh frontline CLL therapy choices, balancing BTK inhibitors vs fixed-duration venetoclax combinations as age, comorbidities, and new trial data guide decisions.

Phase 3 trial shows chemo-free epcoritamab plus lenalidomide cuts progression risk in relapsed DLBCL, with no new safety signals.

Q3 2026 FDA oncology verdicts loom for ADCs and targeted drugs in breast, melanoma, gastric, blood, and lung cancers.

Explore how GI and pancreatic NET sites shape symptoms and survival, plus NCCN-backed therapies from somatostatin analogs to PRRT and cabozantinib.

During a live event, Andrew Brunner, MD, and participants discussed escalating therapy in luspatercept-refractory LR-MDS.

During a live event, Matthew Rettig, MD, and participating oncologists discussed a case of a 74-year-old man with metastatic hormone-sensitive prostate cancer.

FDA issues CRL for Ga-68 edotreotide NET PET kit, citing third-party manufacturing; decentralized SSTR imaging promise remains pending.